Release date: 2014-08-26
The World Health Organization (WHO) said on August 21 that it will hold talks on potential treatments and vaccines for the deadly Ebola outbreak in West Africa early next month.
According to statistics from the United Nations health agencies, there are currently 2,473 infectious diseases in Guinea, Liberia, Nigeria and Sierra Leone, including 1,350 deaths.
WHO this month supported the use of untested drug ZMapp to infect people with Ebola, but the shortage of supplies determines who should be treated first.
In a statement, it will be held from September 4th to 5th to hold talks with researchers and experts who collect the most professional experimental therapies and vaccines in the world.
WHO headquarters is convening more than 100 experts to attend the conference in the areas of pharmaceutical research, clinical management, legal ethics and regulatory issues.
The WHO said that the safety and effectiveness of the drug will be discussed together, which will help accelerate the innovative model of clinical trials and explore those more promising and high-yielding products.
World Health Organization spokesperson Gregory Hartl said that the biomedical ZMapp, previously developed by the American biotechnology company Mapp, has been used on six patients, but now the supply is exhausted.
Of the three Liberian medical workers, two American rescuers have recovered, but the Spanish pastor has died; the other two Liberians have “significantly improved†while another doctor is still in a serious situation.
Source: biodiscover
Tezacaftor Intermediate
Cas 14347-78-5 Tezacaftor Intermediate,Tezacaftor Intermediate,Cas 1004294-65-8,Cas 1638771-94-4 Tezacaftor Intermediate
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com